Stocks Health care XBIO
NASDAQ · Health careXenetic Biosciences, Inc. (XBIO)
Xenetic Biosciences, Inc. brought in $3.3M of revenue over the twelve months to June 30, 2026, up 33.3% from a year earlier. It posted a net loss of $2.5M. At June 30, 2026 it held $6.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Xenetic Biosciences, Inc.
- Net worth
- Xenetic Biosciences, Inc. has a market value (market cap) of $4.2M at the latest share price, and shareholders' equity of $6.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3M (+19.0% year on year), with a net loss of $2.7M. Over the 12 months to June 30, 2026: revenue $3.3M, net loss $2.5M.
- Cash flow
- In fiscal 2025 operations used $2.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Xenetic Biosciences, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Xenetic Biosciences, Inc. does
Xenetic Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XBIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3M | -$2.7M | -$1.58 | n/a |
| 2024 | $2.5M | -$4M | -$2.57 | n/a |
| 2023 | $2.5M | -$4.1M | -$2.71 | n/a |
| 2022 | $1.7M | -$6.6M | -$4.61 | n/a |
| 2021 | $1.2M | -$5.6M | -$5.51 | n/a |
| 2020 | $436.9K | -$10.9M | -$17.04 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where XBIO ranks in Health care
Latest SEC filings
What Xenetic Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 23, 2026
- September 18, 2026Passive stake (5% or more) SCHEDULE 13G
- September 16, 2026
- August 7, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 12% to $660.6K versus the same quarter last year; diluted EPS -$0.41 versus -$0.45.
- May 29, 2026Passive stake (5% or more) SCHEDULE 13G
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 36% to $806.9K versus the same quarter last year; diluted EPS -$0.20 versus -$0.59.
- April 24, 2026Annual report (amended) 10-K/A · period to December 31, 2025Revenue rose 19% to $3M versus the prior year; diluted EPS -$1.58 versus -$2.57.
Insider trades
What the people running Xenetic Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| April 21, 2026 | Parslow James FInterim CEO and CFO | Received as pay | 100,000 | - |
Who owns XBIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Dmitry Genkin13D, may seek influence with 5 related filers | 14% | March 18, 2024 |
| Renaissance Technologies LLC13G, passive with 1 related filers | 6% | May 14, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 100,000 shares in total, about $186.6K at the last price.
| Holder | Shares |
|---|---|
| Parslow James FInterim CEO and CFO | 100,000 |
Questions about XBIO
What does Xenetic Biosciences, Inc. do?
Xenetic Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as XBIO. Its shares trade on NASDAQ under the ticker XBIO.
What is Xenetic Biosciences, Inc.'s net worth?
Xenetic Biosciences, Inc. has a market value (market cap) of $4.2M at the latest share price, and shareholders' equity of $6.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Xenetic Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $2.5M on revenue of $3.3M.
How much revenue does Xenetic Biosciences, Inc. make?
Over the twelve months to June 30, 2026 Xenetic Biosciences, Inc. reported revenue of $3.3M. That is 33.3% more than a year earlier.
When did Xenetic Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 23, 2026.
When is Xenetic Biosciences, Inc.'s next earnings report?
Xenetic Biosciences, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare XBIO with
Follow XBIO
Get an email when Xenetic Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Xenetic Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.